Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00134498
Status:
COMPLETED
Last Update Posted:
2007-11-16
First Post:
2005-08-22
Brief Title:
A Study Comparing The Efficacy Safety Of TorcetrapibAtorvastatin And Atorvastatin In Subjects With High Triglycerides
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Phase 3 Multi-Site Double-Blind Randomized Forced Titration Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of Fixed Combination Torcetrapib CP 529414Atorvastatin Administered Orally Once Daily Qd For Eighteen Weeks Compared With Atorvastatin Alone In Subjects With Fredrickson Type IV Hypertriglyceridemia
Status:
COMPLETED
Status Verified Date:
2007-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The Torcetrapib project was terminated on December 2 2006 due to safety findings
To assess the safety and efficacy of the fixed combination torcetrapibatorvastatin in subjects with Fredrickson Type IV Hypertriglyceridemia
To assess the safety and efficacy of the fixed combination torcetrapibatorvastatin in subjects with Fredrickson Type IV Hypertriglyceridemia
Detailed Description:
For additional information please call 1-800-718-1021
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None